stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Total debt
CRISPR Therapeutics AG's total debt at the end of fiscal 2022 was $228.0M, up 7.04% from $213.0M in fiscal 2021. At the end of the quarter to 30 September 2026 it was $586.9M. Over the past ten years it has ranged from $38.3M (fiscal 2015) to $228.0M (fiscal 2022) — the current reading is the highest in ten years. CRISPR Therapeutics AG ranks 27th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $228.0M | 7.04% |
| FY2021 | $213.0M | 326.00% |
| FY2020 | $50.0M | 13.64% |
| FY2019 | $44.0M | 14.77% |
| FY2015 | $38.3M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $586.9M | 0.13% |
| Jun 2026 | $586.2M | 0.12% |
| Mar 2026 | $585.5M | 157.92% |
| Sep 2023 | $227.0M | (1.30%) |
| 18 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $603.5M |
| CRSP CRISPR Therapeutics AG | $586.9M |
| COGT Cogent Biosciences, Inc. compare | $223.5M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $156.4M |
| ERAS Erasca, Inc. compare | $56.8M |
| DFTX Definium Therapeutics, Inc. compare | $36.5M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement